Skip to main content
AmigoFish

ORBITA-2 & PCI In Older Adults; Smartwatches and AFib Detection; Improved Management and Treatment of HF and HFrFF

From Eagle's Eye View: Your Weekly CV Update From ACC.org · · 8 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In this week's View, Dr. Eagle looks at the ORBITA-2 trial and how percutaneous coronary intervention (PCI) may lead to greater symptom relief in older adults. He then explores the EQUAL trial that investigated how Apple smartwatch monitoring improves atrial fibrillation (AFib) detection. Finally, Dr. Eagle examines revelations from the EMPEROR-Preserved trial regarding interaction between SGLT2 inhibitors and baseline magnesium levels in treating patients who have either heart failure (HF) or HF with preserved ejection fraction (HFpEF).

Subscribe to Eagle's Eye View

Back to Eagle's Eye View: Your Weekly CV Update From ACC.org · Report a problem